PEGS Summit will return to Boston May 1-5, 2017 for another inspiring week-long event providing an exclusive platform for collaboration and discussion among a variety of academic and industry perspectives.
Network with world-class experts from pharma, academia, and government to share information, case studies, and best practices covering a vast area of biologic drug development and hear in-depth presentations on protein and antibody engineering, immunotherapy, oncology, expression, analytical, immunogenicity, and therapeutics.
The Oncology Stream will highlight the great strides and best practices for antibody-based therapeutics, including novel bispecific antibodies, ADCs and immunotherapy approaches that promise improved properties, greater efficacy, and clinical translation. Tools for choosing optimal constructs and combination therapy will enable a significant number of these molecules to advance to the clinic and enable precision targeting of cancer
Antibodies for Cancer Therapy
The Seventh Annual Antibodies for Cancer Therapy meeting has become a critical forum for learning the newest trends in designing antibodies against oncology targets. This meeting will review current strategies and recent developments with novel constructs and emerging targets for oncology. Leaders in the community will discuss advances and share learning experiences with the audience to facilitate knowledge sharing and improve our success rate in this important area. Much progress has been made recently, so don’t miss this chance to gain wisdom that will impact your work.
Advancing Bispecific Antibodies & Combination Therapy to the Clinic
At the Fifth Annual Advancing Bispecific Antibodies and Combination Therapy to the Clinic conference, leaders will share insights and review encouraging clinical data. The proliferation of novel multi-specific antibody constructs and combination therapy approaches has yielded exciting results, and this meeting will delve into solutions for improving the technology and selecting the best molecules for manufacturing and developability concerns.
The Bioconjugation Stream brings together 2 promising and exciting proteins in the category – Fusion Proteins and Antibody-Drug Conjugates – and explores their current and future prospects as therapeutics. The Fusion Protein Therapeutics conference explores the varying constructs of fusion protein molecules to deliver higher efficacy, greater specificity and longer half-lives. The Antibody-Drug Conjugates I conference underlies the industry’s greater understanding of ADC chemistry and biology, prompting creative design and engineering of next-generation linkers, payloads and antibodies; while Antibody-Drug Conjugates II conference invites scientists to share their latest clinical results and lessons learned to help advance their molecules and drive clinical success.
Fusion Protein Therapeutics
The customizable functionality of Fusion Protein Therapeutics creates advantages over antibody-based therapies by combining modular building blocks that can reach targets not accessible to antibodies. Additional advantages include lower patient dosing, reduced production costs, and improved product homogeneity. The Fusion Protein Therapeutics conference explores the varying constructs and ‘designs’ of fusion protein molecules, and will disclose how they are being engineered to form more efficacious therapeutics that offer specificity with enhanced stability and longer half-life. Experts will present case studies from R&D through clinical data, and will share the results they’ve achieved.
This is an exciting time for antibody-drug conjugate developers. With many ADCs moving into later-stage clinical trials, the industry is eagerly anticipating the results from these trials. Some of the lessons learned from earlier trials have already been applied to new generations of ADC design, helping the industry to overcome the setbacks previously experienced. The industry is now eagerly anticipating data from new pivotal trials in solid tumors, results from trials with new payloads and linkers, and outcomes from combination therapies.
Lessons learned from the two marketed ADCs and the ongoing ADC trials have not only enabled scientists to better understand the mechanisms of action of antibody-drug conjugates, but also helped invigorate a new field of ADC study aimed at overcoming the challenges of poor internalization, tumor non-specificity, off-target toxicity, lack of efficacy, low expression levels and multi-drug resistance. Today, scientists continue to innovate on next generation ADCs by improving target selection, finding new cytotoxic drugs as warheads, engineering antibodies or discovering alternative effector moieties to increase half-lives and improve target specificity, optimizing linker-payload chemistry to produce stable and homogeneous ADCs, and overcoming the challenges of multi-drug resistance.
Antibody-Drug Conjugates I: New Targets, Payloads and Chemistry
The Antibody-Drug Conjugates I: New Targets, Payloads and Chemistry conference will present scientists’ creativity in the design and optimization of next-generation bioconjugates.
Antibody-Drug Conjugates II: Advancing Toward the Clinic
During the Antibody-Drug Conjugates II: Advancing Toward the Clinic conference, scientists will present their latest clinical and preclinical data, as well as lessons learned to help drive the industry toward clinical success.